Journey Advisory Group LLC Sells 262 Shares of Johnson & Johnson $JNJ

Journey Advisory Group LLC trimmed its stake in shares of Johnson & Johnson (NYSE:JNJ) by 1.0% in the second quarter, HoldingsChannel reports. The firm owned 26,237 shares of the company’s stock after selling 262 shares during the quarter. Journey Advisory Group LLC’s holdings in Johnson & Johnson were worth $4,008,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of JNJ. GFG Capital LLC bought a new stake in Johnson & Johnson in the 2nd quarter valued at $35,000. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the 1st quarter worth approximately $47,000. 1248 Management LLC bought a new position in Johnson & Johnson during the 1st quarter worth $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the 1st quarter valued at $49,000. Finally, Harvest Fund Management Co. Ltd bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $191.93 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The business’s 50 day simple moving average is $181.27 and its 200 day simple moving average is $165.37. The stock has a market capitalization of $462.23 billion, a PE ratio of 18.53, a PEG ratio of 2.28 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The company had revenue of $24.02 billion during the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on JNJ shares. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Citigroup lifted their price target on Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. Bank of America upped their price objective on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 15th. Morgan Stanley set a $190.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, October 15th. Finally, Wall Street Zen upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $200.06.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.